Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724

Hamster preproglucagon contains the sequence of glucagon and two related peptides

Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 591

Proline-Dependent Structural and Biological Properties of Peptides and Proteins

Yaron, A., Naider, F. R., & Scharpé, S. (1993) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239309082572 · Cited by 551

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamide

Hopsu-Havu, V. K., & Glenner, G. G. (1966) · Histochemistry and Cell Biology · doi:10.1007/bf00577838 · Cited by 437

Entero-Insular Axis

Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists

Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17

Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo

Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00027-1 · Cited by 17

Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: Oxadiazolyl ketones

Koo, K. D., Kim, M. J., Kim, S.-S., Kim, K.-H., Hong, S. Y., Hur, G., Yim, H. J., Kim, G. T., Han, H. O., Kwon, O.-S., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.046 · Cited by 17

Chapter 7 Case History: JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Weber, A. E., & Thornberry, N. A. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42007-3 · Cited by 17

GIP-Based Therapeutics for Diabetes and Obesity

Gault, V. A., Irwin, N., & Flatt, P. R. (2008) · Current Chemical Biology · doi:10.2174/187231308783334108 · Cited by 17

The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets

Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 21

Emerging Role of Caveolin-1 in GLP-1 Action

Puddu, A., & Maggi, D. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.668012 · Cited by 16

Emerging molecular technologies for light-mediated modulation of pancreatic beta-cell function

Chen, Z., Truskinovsky, L. F., & Tzanakakis, E. S. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101552 · Cited by 15

Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors

Park, W. S., Jun, M. A., Shin, M. S., Kwon, S. W., Kang, S. K., Kim, K. Y., Rhee, S. D., Bae, M. A., Narsaiah, B., Lee, D., et al. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.08.001 · Cited by 16

Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1

Park, S.-H., Park, J., Shim, H. M., Na, A., Bae, K.-C., Lim, J.-G., & Song, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.139 · Cited by 17

Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: Use of a carboxylate prodrug to improve bioavailability

Ikuma, Y., Hochigai, H., Kimura, H., Nunami, N., Kobayashi, T., Uchiyama, K., Umezome, T., Sakurai, Y., Sawada, N., Tadano, J., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.051 · Cited by 16

Functional association of the N‐terminal residues with the central region in glucagon‐related peptides

Patterson, J. T., Day, J. W., Gelfanov, V. M., & DiMarchi, R. D. (2011) · Journal of Peptide Science · doi:10.1002/psc.1385 · Cited by 16

Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Salvatore, T., Carbonara, O., Cozzolino, D., Torella, R., & Sasso, F. C. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802076 · Cited by 16

Neuroendocrine Control of Food Intake

Park, S. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.6.391 · Cited by 16

A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus

Bai, X., Niu, Y., Zhu, J., Yang, A.-Q., Wu, Y., & Ye, X. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.036 · Cited by 16

Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine – Review

Torrecillas-Baena, B., Gálvez-Moreno, M. Á., Quesada‐Gómez, J. M., Dorado, G., & Casado‐Díaz, A. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10285-w · Cited by 18

Glucose-Dependent Insulinotropic Polypeptide (GIP)

Wolfe, M. M., Boylan, M. O., Kieffer, T. J., & Tseng, C. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-695-9_18 · Cited by 16

Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats

NISHII, N., Takashima, S., Iguchi, A., Murahata, Y., Matsuu, A., Hikasa, Y., & KITAGAWA, H. (2014) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2014.04.006 · Cited by 16

Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet

Nakaya, K., Kubota, N., Takamoto, I., Kubota, T., Katsuyama, H., Sato, H., Tokuyama, K., Hashimoto, S., Goto, M., Jomori, T., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.010 · Cited by 16

Systemic Delivery of Bioactive Glucagon-Like Peptide 1 after Adenoviral-Mediated Gene Transfer in the Murine Salivary Gland

Voutetakis, A., Cotrim, A. P., Rowzee, A. M., Zheng, C., Rathod, T., Yanık, T., Loh, Y. P., Baum, B. J., & Cawley, N. X. (2010) · Endocrinology · doi:10.1210/en.2010-0193 · Cited by 16

Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery

Wang, M., Liu, Q., & Zhou, C. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.107 · Cited by 16

Oligonucleotide sequencing using guanine-specific methylation and electrospray ionization ion trap mass spectrometry

Marzilli, L. A., Barry, J. P., Sells, T. B., Law, S., Vouros, P., & Harsch, A. (1999) · Journal of Mass Spectrometry · doi:10.1002/(sici)1096-9888(199904)34:4 · Cited by 19

Therapeutic Potential of Dipeptidyl Peptidase-IV Inhibitors in Patients With Diabetes Mellitus

Moore, K. B., & Saudek, C. D. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180ed42dc · Cited by 15

Pyrazolidine Derivatives with Heteroaryl Urea as Dipeptidyl Peptidase IV Inhibitors

Ahn, J. H., Jung, S. H., Kim, J. A., Song, S. B., Kwon, S. J., Kim, K. R., Rhee, S. D., Park, S.-D., Lee, J., Kim, S. S., et al. (2005) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.53.1048 · Cited by 16

ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity

Matsuyama‐Yokono, A., Tahara, A., Nakano, R., Someya, Y., Nagase, I., Hayakawa, M., & Shibasaki, M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.03.021 · Cited by 16

Valine Pyrrolidide Preserves Intact Glucose‐Dependent Insulinotropic Peptide and Improves Abnormal Glucose Tolerance in Minipigs With Reduced β‐Cell Mass

Larsen, M. O., Rolin, B., Ribel, U., Wilken, M., Deacon, C. F., Svendsen, O., Gotfredsen, C. F., & Carr, R. D. (2003) · Journal of Diabetes Research · doi:10.1155/edr.2003.93 · Cited by 17

Physiology and clinical applications of GIP

Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 15

Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery

Kweon, S., Lee, J.-H., Yang, S.-B., Park, S. J., Subedi, L., Shim, J., Cho, S., Choi, J. U., Byun, Y., Park, J., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00421-7 · Cited by 15

The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model

Shang, Q., Liu, M. K., Saumoy, M., Holst, J. J., Salen, G., & Xu, G. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00295.2011 · Cited by 15

Coumaglutide, a novel long-acting GLP-1 analog, inhibits β-cell apoptosis in vitro and invokes sustained glycemic control in vivo

Sun, L., Wang, C., Dai, Y., Chu, Y., Han, J. D. J., Zhou, J., Cai, X., Huang, W., & Qian, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.028 · Cited by 15

Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4

Wu, L., Zhou, M., Xie, Y., Lang, H., Li, T., Yi, L., Zhang, Q., & Mi, M. (2022) · Nutrients · doi:10.3390/nu14214583 · Cited by 15

Role and development of GLP-1 receptor agonists in the management of diabetes.

Chia, C. W., & Egan, J. M. (2009) · Europe PMC (PubMed Central) · Cited by 15

A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction

Patterson, J. T., Li, P., Day, J. W., Gelfanov, V. M., & DiMarchi, R. D. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.01.003 · Cited by 15

Discovery of β-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV

Nordhoff, S., Cerezo, S., Deppe, H., Hill, O., López-Canet, M., Rummey, C., Thiemann, M., Matassa, V. G., Edwards, P. J., & Feurer, A. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.109 · Cited by 15

The Expression and Function of Glucose-Dependent Insulinotropic Polypeptide in the Embryonic Mouse Pancreas

Prasadan, K. L., Koizumi, M., Tulachan, S., Shiota, C., Lath, N. R., Paredes, J. L., Guo, P., El‐Gohary, Y., Malek, M. M., Shah, S. R., et al. (2011) · Diabetes · doi:10.2337/db09-0035 · Cited by 14

Extending Residence Time and Stability of Peptides by Protected Graft Copolymer (PGC) Excipient: GLP-1 Example

Castillo, G. M., Reichstetter, S., & Bolotin, E. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0542-2 · Cited by 15

A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth

Kim, H. Y., Hwang, J., Moon, M. J., & Seong, J. Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.3.320 · Cited by 15

Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists

Jones, L. H., & Price, D. A. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00002-8 · Cited by 15

Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists

Gault, V. A., Hunter, K., Irwin, N., Green, B. D., Greer, B., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.001 · Cited by 15

Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration

Kondo, T., Nekado, T., Sugimoto, I., Ochi, K., Takai, S., Kinoshita, A., Tajima, Y., Yamamoto, S., Kawabata, K., Nakai, H., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.041 · Cited by 15

3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes

Coumar, M. S., Chang, C., Chen, C., Chen, X., Chien, C., Tsai, T., Cheng, J., Wu, H., Han, C.-H., Wu, S., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.019 · Cited by 15

Review: DPP IV inhibitors - current evidence and future directions

Vilsbøll, T., & Knop, F. K. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070020401 · Cited by 16

The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management

Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15

Dietary Synergies in Appetite Control: Distal Gastrointestinal Tract

Woods, S. C. (2006) · Obesity · doi:10.1038/oby.2006.301 · Cited by 15

Mechanisms underlying the prokinetic effects of endogenous glucagon-like peptide-1 in the rat proximal colon

Nakamori, H., Iida, K., & Hashitani, H. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00175.2021 · Cited by 14

GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer’s Disease through its Supporting DPP4 Inhibitors: A Review

Abubakar, M., Nama, L., Ansari, M. M., Ansari, M. M., Bhardwaj, S., Daksh, R., Syamala, K. L. V., Jamadade, M. S., Chhabra, V., Kumar, D., et al. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266293416240515075450 · Cited by 14

Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells

Chehade, J. M., Alcalde, R., Naem, E., Mooradian, A. D., Wong, N. C. W., & Haas, M. J. (2012) · Metabolism · doi:10.1016/j.metabol.2012.07.005 · Cited by 15

Combined treatment with a dipeptidyl peptidase‐IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells

Liang, J. B., Leung, K. K., Lam, S. Y., & Leung, P. S. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01612.x · Cited by 14

Glucagon‐Like Peptide‐1 Formulation – the Present and Future Development in Diabetes Treatment

Lee, C. Y. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12524 · Cited by 14

Liraglutide protects pancreatic beta cells during an early intervention in G ato‐ K akizaki rats (Gato‐Kakizaki大鼠使用利拉鲁肽进行早期干预可以保护胰腺β细胞)

Luo, X., Pan, L., Nie, A., Wang, Q., Gu, Y., Li, F., Zhang, H., Li, W., & Li, X. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12061 · Cited by 14

Neuroprotective role of (Val 8 ) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease

Liu, Y., Li, L., Liu, K., Zhao, J., Hölscher, C., & Li, G. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177742 · Cited by 14

Study on the Mechanism of the Blood-Glucose-Lowering Effect of Collagen Peptides from Sturgeon By-Products

Sasaoka, Y., Takagi, T., Michiba, S., Yamamoto, Y., Kumagai, Y., & Kishimura, H. (2021) · Marine Drugs · doi:10.3390/md19100584 · Cited by 14

Incretin hormones and beta cell function in chronic pancreatitis.

Knop, F. K. (2010) · PubMed · Cited by 14

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus

Kim, M., & Lee, M. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.1.2 · Cited by 14

Revisiting the Diabetes-Heart Failure Connection

Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14

Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors

Park, W. S., Kang, S. K., Jun, M. A., Shin, M. S., Kim, K. Y., Rhee, S. D., Bae, M. A., Kim, M. S., Kim, K. R., Kang, N. S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.041 · Cited by 14

A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure

Asakawa, T., Moritoh, Y., Kataoka, O., Suzuki, N., Takeuchi, K., & Odaka, H. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.04.024 · Cited by 14

Approaches to the pharmacological treatment of obesity

Salem, V., & Bloom, S. R. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.54 · Cited by 15

Nanoparticles induced by embedding self‐assembling cassette into glucagon‐like peptide 1 for improving in vivo stability

Li, Y., Cui, T., Kong, X., Yi, X., Kong, D., Zhang, J., Liu, C., & Gong, M. (2018) · The FASEB Journal · doi:10.1096/fj.201701033rrr · Cited by 14

Exenatide: Its position in the treatment of type 2 diabetes

Guerci, B., & Martin, C. S. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.03.004 · Cited by 14

Recent Advances in the Development of Agents for the Treatment of Type 2 Diabetes

Cobb, J. E., & Dukes, I. D. (1998) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61086-6 · Cited by 14

Glucose-dependent Insulinotropic Polypeptide (GIP): Development of DP IV-Resistant Analogues with Therapeutic Potential

Hinke, S. A., Lynn, F. C., Ehses, J. A., Pamir, N., Manhart, S., Kühn‐Wache, K., Rosche, F., Demuth, H.-U., Pederson, R. A., & McIntosh, C. H. S. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_35 · Cited by 14

Treatment of diabetes with glucagon-like peptide-1 gene therapy

Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13

The latest pharmacotherapy options for type 1 diabetes

Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13

What Has Bariatric Surgery Taught Us About the Role of the Upper Gastrointestinal Tract in the Regulation of Postprandial Glucose Metabolism?

Ma, J., & Vella, A. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00324 · Cited by 14

(R)-3-Amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: Design, synthesis, biological evaluation, and molecular modeling

Wang, S., Su, M., Wang, J., Li, Z., Zhang, L. J., Ji, X., Li, J., Li, J., & Liu, H. S. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.09.051 · Cited by 13

New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus

Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13

Dual-Monoclonal, Sandwich Immunoassay Specific for Glucose-Dependent Insulinotropic Peptide1-42, the Active Form of the Incretin Hormone

Troutt, J. S., Siegel, R. W., Chen, J., Sloan, J. H., Deeg, M. A., Cao, G., & Konrad, R. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.159954 · Cited by 13

Characterization of the Exocrine Pancreas in the Male Zucker Diabetic Fatty Rat Model of Type 2 Diabetes Mellitus Following 3 Months of Treatment With Sitagliptin

Forest, T. W., Holder, D., Smith, A., Cunningham, C., Yao, X., Dey, M., Frederick, C. B., & Prahalada, S. R. (2014) · Endocrinology · doi:10.1210/en.2013-1781 · Cited by 13

Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides

Aziz, A. A., Anderson, G. H., Giacca, A., & Cho, F. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00850.2004 · Cited by 12

Biology and therapeutic potential of GLP-1 in the treatment of diabetes

Chia, C. W., & Egan, J. M. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.08.013 · Cited by 13

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo

Someya, Y., Tahara, A., Nakano, R., Matsuyama‐Yokono, A., Nagase, I., Fukunaga, Y., Takasu, T., Hayakawa, M., & Shibasaki, M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0277-8 · Cited by 13

Nutrient regulation of pancreatic β-cell function in diabetes: problems and potential solutions

Flatt, P. R., & Green, B. D. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340774 · Cited by 13

Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration

Ruggles, J. A., Kelemen, D. W., & Baron, A. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00098-7 · Cited by 12

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties

Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14

Incretin Hormones: Mechanisms, Therapeutic Implications, and Future Directions in Glucose Regulation and Diabetes Management

Zargar, A. A., Mehta, V., Huddar, V., Gupta, R., Bhandari, K., Posa, M. K., Ramya, T. S., Snigdha, D., Vijayakumar, B., Sharma, M. C., et al. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100014 · Cited by 15

Molecular Basis of cAMP Signaling in Pancreatic β Cells

Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_25 · Cited by 11

Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances

Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 127

Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues

Kamoi, K., Shinozaki, Y., Furukawa, K., & Sasaki, H. (2011) · Endocrine Journal · doi:10.1507/endocrj.k11e-125 · Cited by 12

Active glucagon-like peptide-1 (GLP-1): Storage of human plasma and stability over time

Marino, L. D., Griffo, E., Maione, S., & Mirabella, M. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.05.011 · Cited by 12

Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus

Das, A., Geetha, K. M., & Hazarika, I. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09927-y · Cited by 12

Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction

Esser, N., Mongovin, S. M., Parilla, J. H., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J., Akter, R., Hull, R. L., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00234.2021 · Cited by 12

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

Ismaeil, A., Babiker, F. A., & Al‐Sabah, S. (2022) · Pharmaceuticals · doi:10.3390/ph15060720 · Cited by 12

Novel Pentapeptide GLP ‐1 (32–36) Amide Inhibits β‐Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin‐Induced Diabetic Mice

Sun, L., Dai, Y., Wang, C., Chu, Y., Su, X., Yang, J., Zhou, J., Huang, W., & Qian, H. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12615 · Cited by 12

Genetic Variation in the GCG and in the GLP1R Genes and Antipsychotic-Induced Weight Gain

Brandl, E. J., Tiwari, A. K., Chowdhury, N. I., Zai, C. C. H., Lieberman, J. A., Meltzer, H. Y., Kennedy, J. L., & Müller, D. J. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.247 · Cited by 12

Normal Response of Active GLP-1 Level like Substances to Test Meal in Non-Obese Type 2 Diabetic Japanese Patients with Complications and Receiving Treatments

Kamoi, K., Ohara, N., Ikarashi, T., Shinozaki, Y., & Furukawa, K. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000147 · Cited by 12

Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice

Xu, F., Wang, K. Y., Wang, N., Li, G., & Liu, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181939 · Cited by 12

Incretins: B eyond type 2 diabetes

Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 13

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide

Lv, J., Pan, Y., Li, X., Cheng, D., Liu, S., Shi, H., & Zhang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096833 · Cited by 12

Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: Synthesis, SAR and biological evaluation

Kim, H. J., Kwak, W. Y., Min, J. P., Sung, S. Y., Kim, H. D., Kim, M.-K., Kim, H. S., Park, K. J., Son, M. H., Kim, S. H., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.019 · Cited by 12

Practical and Economical Approach to Synthesize Sitagliptin

Lin, K., Cai, Z., & Zhou, W. (2013) · Synthetic Communications · doi:10.1080/00397911.2013.773353 · Cited by 12

Neural and Hormonal Controls of Food Intake and Satiety

Moran, T. H. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50037-4 · Cited by 12

Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

Lingvay, I., Rhee, C., & Raskin, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_10 · Cited by 12

Food and Fluid Intake

Moran, T. H., & Sakai, R. R. (2003) · Wiley eBooks · doi:10.1002/0471264385.wei0311 · Cited by 12

Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC–MS/MS and its application in a pharmacokinetics study

Deng, J., Guo, J., Dai, R., Zhang, G., & Xie, H. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.08.033 · Cited by 11

Magainin-Related Peptides Stimulate Insulin-Release and Improve Glucose Tolerance in High Fat Fed Mice

Ojo, O. O., Srinivasan, D. K., Owolabi, B. O., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2015) · Protein and Peptide Letters · doi:10.2174/0929866521666141229105757 · Cited by 11

Glucose dependent insulinotropic polypeptide and dipeptidyl peptidase inhibitors: Their roles in management of type 2 diabetes mellitus

Gupta, A., Al-Aubaidy, H. A., & Mohammed, B. I. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.03.013 · Cited by 11

Peroral peptide delivery: Peptidase inhibition as a key concept for commercial drug products

Werle, M., & Föger, F. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.028 · Cited by 11

Current Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia

Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 11

Current Research of the RAS in Diabetes Mellitus

Leung, P. S. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-9060-7_8 · Cited by 10

Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585e3596

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S.-J. (1995)

Investigation of metabolism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) by dipeptidyl peptidase IV (DP IV)

Pauly, R. P. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0087239

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 146

The enteroinsular axis in dipeptidyl peptidase IV-negative rats

Pederson, R. A., Kieffer, T. J., Pauly, R. P., Kofod, H., Kwong, J., & McIntosh, C. H. S. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90112-2 · Cited by 49

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

Deacon, C. F., Danielsen, P. L., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145